4umx - Revision history

OCA at 10:30, 10 January 2024

OCA — Wed, 10 Jan 2024 10:30:42 GMT

←Older revision		Revision as of 10:30, 10 January 2024
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4umx]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4UMX OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4UMX FirstGlance]. <br>		<table><tr><td colspan='2'>[[4umx]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4UMX OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4UMX FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NAP:NADP+NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NAP</scene>, <scene name='pdbligand=VVS:2,6-BIS(1H-IMIDAZOL-1-YLMETHYL)-4-(2,4,4-TRIMETHYLPENTAN-2-YL)PHENOL'>VVS</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.88Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NAP:NADP+NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NAP</scene>, <scene name='pdbligand=VVS:2,6-BIS(1H-IMIDAZOL-1-YLMETHYL)-4-(2,4,4-TRIMETHYLPENTAN-2-YL)PHENOL'>VVS</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4umx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4umx OCA], [https://pdbe.org/4umx PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4umx RCSB], [https://www.ebi.ac.uk/pdbsum/4umx PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4umx ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4umx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4umx OCA], [https://pdbe.org/4umx PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4umx RCSB], [https://www.ebi.ac.uk/pdbsum/4umx PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4umx ProSAT]</span></td></tr>
	</table>		</table>

OCA at 08:29, 22 March 2023

OCA — Wed, 22 Mar 2023 08:29:55 GMT

←Older revision		Revision as of 08:29, 22 March 2023
Line 3:		Line 3:
	<StructureSection load='4umx' size='340' side='right'caption='[[4umx]], [[Resolution\|resolution]] 1.88Å' scene=''>		<StructureSection load='4umx' size='340' side='right'caption='[[4umx]], [[Resolution\|resolution]] 1.88Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4umx]] is a 2 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4UMX OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4UMX FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4umx]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4UMX OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4UMX FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NAP:NADP+NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NAP</scene>, <scene name='pdbligand=VVS:2,6-BIS(1H-IMIDAZOL-1-YLMETHYL)-4-(2,4,4-TRIMETHYLPENTAN-2-YL)PHENOL'>VVS</scene~~></td></tr>~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NAP:NADP+NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NAP</scene>, <scene name='pdbligand=VVS:2,6-BIS(1H-IMIDAZOL-1-YLMETHYL)-4-(2,4,4-TRIMETHYLPENTAN-2-YL)PHENOL'>VVS</scene></td></tr>
-	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4umy\|4umy]]</td></tr>~~	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4umx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4umx OCA], [https://pdbe.org/4umx PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4umx RCSB], [https://www.ebi.ac.uk/pdbsum/4umx PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4umx ProSAT]</span></td></tr>
-	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Isocitrate_dehydrogenase_(NADP(+)) Isocitrate dehydrogenase (NADP(+))], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.42 1.1.1.42] </span></td></tr>	+
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4umx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4umx OCA], [~~http~~://pdbe.org/4umx PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=4umx RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/4umx PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=4umx ProSAT]</span></td></tr>	+
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/IDHC_HUMAN IDHC_HUMAN]] Defects in IDH1 are involved in the development of glioma (GLM) [MIM:[~~http~~://omim.org/entry/137800 137800]]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Mutations affecting Arg-132 are tissue-specific, and suggest that this residue plays a unique role in the development of high-grade gliomas. Mutations of Arg-132 to Cys, His, Leu or Ser abolish magnesium binding and abolish the conversion of isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is converted to R(-)-2-hydroxyglutarate. Elevated levels of R(-)-2-hydroxyglutarate are correlated with an elevated risk of malignant brain tumors.	+	[https://www.uniprot.org/uniprot/IDHC_HUMAN IDHC_HUMAN] Defects in IDH1 are involved in the development of glioma (GLM) [MIM:[https://omim.org/entry/137800 137800]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Mutations affecting Arg-132 are tissue-specific, and suggest that this residue plays a unique role in the development of high-grade gliomas. Mutations of Arg-132 to Cys, His, Leu or Ser abolish magnesium binding and abolish the conversion of isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is converted to R(-)-2-hydroxyglutarate. Elevated levels of R(-)-2-hydroxyglutarate are correlated with an elevated risk of malignant brain tumors.
		+	== Function ==
		+	[https://www.uniprot.org/uniprot/IDHC_HUMAN IDHC_HUMAN]
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 27:		Line 27:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Marquette~~, J P~~]]	+	[[Category: Marquette JP]]
-	[[Category: Mathieu, M]]	+	[[Category: Mathieu M]]
-	~~[[Category: Isocitrate dehydrogenase inhibitor]]~~	+
-	~~[[Category: Oxidoreductase~~]]	+

OCA at 10:47, 26 February 2020

OCA — Wed, 26 Feb 2020 10:47:15 GMT

←Older revision		Revision as of 10:47, 26 February 2020
Line 1:		Line 1:

	==IDH1 R132H in complex with cpd 1==		==IDH1 R132H in complex with cpd 1==
-	<StructureSection load='4umx' size='340' side='right' caption='[[4umx]], [[Resolution\|resolution]] 1.88Å' scene=''>	+	<StructureSection load='4umx' size='340' side='right'caption='[[4umx]], [[Resolution\|resolution]] 1.88Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4umx]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4UMX OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4UMX FirstGlance]. <br>		<table><tr><td colspan='2'>[[4umx]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4UMX OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4UMX FirstGlance]. <br>
Line 20:		Line 20:
	</div>		</div>
	<div class="pdbe-citations 4umx" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 4umx" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Isocitrate dehydrogenase 3D structures\|Isocitrate dehydrogenase 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
Line 25:		Line 28:
	</StructureSection>		</StructureSection>
	[[Category: Human]]		[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Marquette, J P]]		[[Category: Marquette, J P]]
	[[Category: Mathieu, M]]		[[Category: Mathieu, M]]
	[[Category: Isocitrate dehydrogenase inhibitor]]		[[Category: Isocitrate dehydrogenase inhibitor]]
	[[Category: Oxidoreductase]]		[[Category: Oxidoreductase]]

OCA at 22:41, 15 November 2017

OCA — Wed, 15 Nov 2017 22:41:11 GMT

←Older revision		Revision as of 22:41, 15 November 2017
Line 3:		Line 3:
	<StructureSection load='4umx' size='340' side='right' caption='[[4umx]], [[Resolution\|resolution]] 1.88Å' scene=''>		<StructureSection load='4umx' size='340' side='right' caption='[[4umx]], [[Resolution\|resolution]] 1.88Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4umx]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4UMX OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4UMX FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4umx]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4UMX OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4UMX FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NAP:NADP+NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NAP</scene>, <scene name='pdbligand=VVS:2,6-BIS(1H-IMIDAZOL-1-YLMETHYL)-4-(2,4,4-TRIMETHYLPENTAN-2-YL)PHENOL'>VVS</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NAP:NADP+NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NAP</scene>, <scene name='pdbligand=VVS:2,6-BIS(1H-IMIDAZOL-1-YLMETHYL)-4-(2,4,4-TRIMETHYLPENTAN-2-YL)PHENOL'>VVS</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4umy\|4umy]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4umy\|4umy]]</td></tr>
Line 20:		Line 20:
	</div>		</div>
	<div class="pdbe-citations 4umx" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 4umx" style="background-color:#fffaf0;"></div>
-
-	==See Also==
-	*[[Isocitrate dehydrogenase\|Isocitrate dehydrogenase]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
	[[Category: Marquette, J P]]		[[Category: Marquette, J P]]
	[[Category: Mathieu, M]]		[[Category: Mathieu, M]]
	[[Category: Isocitrate dehydrogenase inhibitor]]		[[Category: Isocitrate dehydrogenase inhibitor]]
	[[Category: Oxidoreductase]]		[[Category: Oxidoreductase]]

OCA at 19:38, 11 August 2016

OCA — Thu, 11 Aug 2016 19:38:21 GMT

←Older revision		Revision as of 19:38, 11 August 2016
Line 1:		Line 1:
		+
	==IDH1 R132H in complex with cpd 1==		==IDH1 R132H in complex with cpd 1==
	<StructureSection load='4umx' size='340' side='right' caption='[[4umx]], [[Resolution\|resolution]] 1.88Å' scene=''>		<StructureSection load='4umx' size='340' side='right' caption='[[4umx]], [[Resolution\|resolution]] 1.88Å' scene=''>
Line 6:		Line 7:
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4umy\|4umy]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4umy\|4umy]]</td></tr>
	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Isocitrate_dehydrogenase_(NADP(+)) Isocitrate dehydrogenase (NADP(+))], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.42 1.1.1.42] </span></td></tr>		<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Isocitrate_dehydrogenase_(NADP(+)) Isocitrate dehydrogenase (NADP(+))], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.42 1.1.1.42] </span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4umx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4umx OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4umx RCSB], [http://www.ebi.ac.uk/pdbsum/4umx PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4umx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4umx OCA], [http://pdbe.org/4umx PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4umx RCSB], [http://www.ebi.ac.uk/pdbsum/4umx PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4umx ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 18:		Line 19:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
		+	<div class="pdbe-citations 4umx" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Isocitrate dehydrogenase\|Isocitrate dehydrogenase]]
	== References ==		== References ==
	<references/>		<references/>

OCA at 14:12, 25 December 2014

OCA — Thu, 25 Dec 2014 14:12:43 GMT

←Older revision		Revision as of 14:12, 25 December 2014
Line 10:		Line 10:
	== Disease ==		== Disease ==
	[[http://www.uniprot.org/uniprot/IDHC_HUMAN IDHC_HUMAN]] Defects in IDH1 are involved in the development of glioma (GLM) [MIM:[http://omim.org/entry/137800 137800]]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Mutations affecting Arg-132 are tissue-specific, and suggest that this residue plays a unique role in the development of high-grade gliomas. Mutations of Arg-132 to Cys, His, Leu or Ser abolish magnesium binding and abolish the conversion of isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is converted to R(-)-2-hydroxyglutarate. Elevated levels of R(-)-2-hydroxyglutarate are correlated with an elevated risk of malignant brain tumors.		[[http://www.uniprot.org/uniprot/IDHC_HUMAN IDHC_HUMAN]] Defects in IDH1 are involved in the development of glioma (GLM) [MIM:[http://omim.org/entry/137800 137800]]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Mutations affecting Arg-132 are tissue-specific, and suggest that this residue plays a unique role in the development of high-grade gliomas. Mutations of Arg-132 to Cys, His, Leu or Ser abolish magnesium binding and abolish the conversion of isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is converted to R(-)-2-hydroxyglutarate. Elevated levels of R(-)-2-hydroxyglutarate are correlated with an elevated risk of malignant brain tumors.
-	== Function ==
-
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==

OCA at 06:04, 26 November 2014

OCA — Wed, 26 Nov 2014 06:04:22 GMT

←Older revision		Revision as of 06:04, 26 November 2014
Line 12:		Line 12:
	== Function ==		== Function ==

		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Cancer-associated point mutations in isocitrate dehydrogenase 1 and 2 (IDH1, IDH2) confer a neomorphic enzymatic activity: the reduction of alpha-ketoglutarate (alphaKG) to D-2-hydroxyglutaric acid (2HG), which is proposed to act as an oncogenic metabolite by inducing hypermethylation of histones and DNA. While selective inhibitors of mutant IDH1 and IDH2 have been identified and are currently under investigation as potential cancer therapeutics, the mechanistic basis for their selectivity is not yet well-understood. A high-throughput screen for selective inhibitors of IDH1 bearing the oncogenic mutation R132H identified Compound 1, a bis-imidazole phenol that inhibits 2HG production in cells. We investigated the mode of inhibition of Compound 1 and a previously published IDH1 mutant inhibitor with a different chemical scaffold. Steady-state kinetics and biophysical studies show that both of these compounds selectively inhibit mutant IDH1 by binding to an allosteric site, and that inhibition is competitive with respect to Mg2+. A crystal structure of Compound 1 complexed with R132H IDH1 indicates that the inhibitor binds at the dimer interface and makes a direct contact with a residue involved in binding of the catalytically essential divalent cation. These results show that targeting a divalent cation binding residue can enable selective inhibition of mutant IDH1, and suggest that differences in magnesium binding between wild-type and mutant enzymes may contribute to the inhibitors' selectivity for the mutant enzyme.
		+
		+	Selective Inhibition of Mutant Isocitrate Dehydrogenase 1 (IDH1) via Disruption of a Metal Binding Network by an Allosteric Small Molecule.,Deng G, Shen J, Yin M, McManus J, Mathieu M, Gee P, He T, Shi C, Bedel O, McLean LR, Le-Strat F, Zhang Y, Marquette JP, Gao Q, Zhang B, Rak A, Hoffmann D, Rooney E, Vassort A, Englaro W, Li Y, Patel V, Adrian F, Gross S, Wiederschain D, Cheng H, Licht S J Biol Chem. 2014 Nov 12. pii: jbc.M114.608497. PMID:25391653<ref>PMID:25391653</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>

OCA at 12:59, 19 November 2014

OCA — Wed, 19 Nov 2014 12:59:04 GMT

←Older revision		Revision as of 12:59, 19 November 2014
Line 1:		Line 1:
-	'''~~Unreleased~~ structure'''	+	==IDH1 R132H in complex with cpd 1==
		+	<StructureSection load='4umx' size='340' side='right' caption='[[4umx]], [[Resolution\|resolution]] 1.88Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[4umx]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4UMX OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4UMX FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NAP:NADP+NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NAP</scene>, <scene name='pdbligand=VVS:2,6-BIS(1H-IMIDAZOL-1-YLMETHYL)-4-(2,4,4-TRIMETHYLPENTAN-2-YL)PHENOL'>VVS</scene></td></tr>
		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4umy\|4umy]]</td></tr>
		+	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Isocitrate_dehydrogenase_(NADP(+)) Isocitrate dehydrogenase (NADP(+))], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.42 1.1.1.42] </span></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4umx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4umx OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4umx RCSB], [http://www.ebi.ac.uk/pdbsum/4umx PDBsum]</span></td></tr>
		+	</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/IDHC_HUMAN IDHC_HUMAN]] Defects in IDH1 are involved in the development of glioma (GLM) [MIM:[http://omim.org/entry/137800 137800]]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Mutations affecting Arg-132 are tissue-specific, and suggest that this residue plays a unique role in the development of high-grade gliomas. Mutations of Arg-132 to Cys, His, Leu or Ser abolish magnesium binding and abolish the conversion of isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is converted to R(-)-2-hydroxyglutarate. Elevated levels of R(-)-2-hydroxyglutarate are correlated with an elevated risk of malignant brain tumors.
		+	== Function ==

-	~~The entry 4umx is ON HOLD until Paper Publication~~	+	__TOC__
-		+	</StructureSection>
-	~~Authors~~: ~~Mathieu, M.,~~ Marquette, J.P.	+	[[Category: Marquette, J P]]
-		+	[[Category: Mathieu, M]]
-	~~Description~~: ~~IDH1 R132H in complex with cpd 1~~	+	[[Category: Isocitrate dehydrogenase inhibitor]]
		+	[[Category: Oxidoreductase]]

OCA: Protected "4umx" [edit=sysop:move=sysop]

OCA — Wed, 28 May 2014 08:37:38 GMT

Protected "4umx" [edit=sysop:move=sysop]

←Older revision

Revision as of 08:37, 28 May 2014

OCA: New page: '''Unreleased structure''' The entry 4umx is ON HOLD until Paper Publication Authors: Mathieu, M., Marquette, J.P. Description: IDH1 R132H in complex with cpd 1

OCA — Wed, 28 May 2014 08:37:36 GMT

New page: '''Unreleased structure''' The entry 4umx is ON HOLD until Paper Publication Authors: Mathieu, M., Marquette, J.P. Description: IDH1 R132H in complex with cpd 1

New page

'''Unreleased structure'''

The entry 4umx is ON HOLD until Paper Publication

Authors: Mathieu, M., Marquette, J.P.

Description: IDH1 R132H in complex with cpd 1